Chitosan Supplementation Improves Hepatic Steatosis, Liver Stiffness, and Body Composition in Patients with Metabolic Dysfunction–Associated Steatotic Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
In a randomized, double-blind, placebo-controlled trial of 60 adults with metabolic dysfunction–associated steatotic liver disease (MASLD), eight weeks of chitosan supplementation significantly improved hepatic steatosis and body composition with a favorable safety profile, though its effect on liver stiffness was not statistically significant after adjustment.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The liver is the body's tireless chemical plant, filtering blood, processing nutrients, and managing energy. When this organ becomes overwhelmed by fat, a condition known as metabolic dysfunction–associated steatotic liver disease, or MASLD, it begins to struggle. This is not merely a matter of excess weight; it is a complex metabolic disorder where fat accumulates inside liver cells, often driven by insulin resistance and a diet high in sugars and saturated fats. Over time, this fatty buildup can inflame the organ, stiffen its tissues, and lead to serious damage, yet there are currently no approved medicines specifically designed to treat it. Doctors rely almost entirely on lifestyle changes, such as diet and exercise, which are difficult for many people to maintain over the long term. Because the liver is central to overall health and because cardiovascular disease remains the leading cause of death for those with this condition, finding safe, effective ways to reduce liver fat has become a critical goal for researchers worldwide.
In a recent clinical trial, scientists investigated whether a natural substance called chitosan could help reverse these changes. Chitosan is a fiber derived from the shells of shellfish, known for its ability to bind to fats in the digestive system. While previous studies had looked at its effects on weight or cholesterol in general populations, this study focused specifically on people diagnosed with MASLD. The researchers wanted to see if taking chitosan supplements, alongside standard dietary advice, could actually clear fat from the liver and improve the organ's health. To find out, they conducted a rigorous, eight-week experiment involving sixty adults who had moderate levels of liver fat. The study was designed so that neither the participants nor the doctors knew who was receiving the actual supplement and who was receiving a harmless placebo, ensuring that the results would be based purely on the effects of the substance itself.
The participants were divided into two groups. One group took six capsules a day, totaling 3,000 milligrams of chitosan, while the other group took identical-looking capsules filled with a neutral filler. Both groups received the same guidance on eating a balanced, slightly lower-calorie diet. The researchers measured the health of the liver at the start and at the end of the eight weeks using a specialized ultrasound technique that can visualize fat and measure how stiff the liver tissue is. They also tracked changes in body weight, waist size, and body fat composition. The results were striking. The group taking chitosan showed a significant reduction in the amount of fat inside their liver cells compared to the placebo group. This improvement was not just a minor fluctuation; it was a clear, measurable drop in liver fat severity that remained significant even after accounting for other factors like changes in body weight or physical activity.
Beyond the liver itself, the supplement appeared to have a positive ripple effect on the body's overall composition. People in the chitosan group lost an average of 1.8 kilograms of body weight, while those in the placebo group actually gained a small amount of weight. More importantly, the chitosan group saw a substantial decrease in their total body fat mass, losing an average of 2.56 kilograms, whereas the placebo group gained fat. Their waistlines also shrank significantly, dropping by more than four centimeters on average. These changes suggest that the supplement helped the body manage fat more effectively, not just by blocking absorption in the gut, but perhaps by influencing how the body processes and stores energy. While the chitosan group showed a small, non-significant reduction in liver stiffness compared to the placebo group, this specific result did not remain statistically significant after adjusting for other factors, meaning there was no definitive evidence that the supplement reduced tissue scarring or inflammation in this short trial.
Throughout the eight weeks, the supplement proved to be safe and well-tolerated. The only side effects reported were mild digestive issues like bloating, which occurred at similar rates in both groups and were likely related to the fiber content of the capsules rather than the active ingredient. Crucially, the study found that the benefits did not come from the participants eating less or changing their exercise habits, as their reported food intake and activity levels remained stable throughout the trial. This points to a direct biological effect of the chitosan on the liver and metabolism. While the study was relatively short and involved a modest number of people, it provides the first solid evidence from a controlled human trial that chitosan can specifically target liver fat in people with this disease. The findings suggest that this natural fiber could become a valuable tool in the management of metabolic liver disease, offering a new avenue for treatment where few options currently exist.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.